Literature DB >> 10859370

Dengue virus type 1 DNA vaccine induces protective immune responses in rhesus macaques.

K Raviprakash1, K R Porter, T J Kochel, D Ewing, M Simmons, I Phillips, G S Murphy, W R Weiss, C G Hayes.   

Abstract

A candidate DNA vaccine expressing dengue virus type 1 pre-membrane and envelope proteins was used to immunize rhesus macaques. Monkeys were immunized intramuscularly (i.m.) or intradermally (i.d.) by three or four 1 mg doses of vaccine, respectively. Monkeys that were inoculated i.m. seroconverted more quickly and had higher antibody levels than those that were inoculated i.d. The sera exhibited virus-neutralizing activity, which declined over time. Four of the eight i.m.-inoculated monkeys were protected completely from developing viraemia when challenged 4 months after the last dose with homologous dengue virus. The other four monkeys had reduced viraemia compared with the control immunized monkeys. The i.d. -inoculated monkeys showed no reduction in viraemia when challenged with the virus. All vaccinated monkeys showed an anamnestic antibody response, indicating that they had established immunological memory. Vaccine-induced antibody had an avidity index similar to that of antibody induced by virus infection; however, no clear correlation was apparent between antibody avidity and virus neutralization titres.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10859370     DOI: 10.1099/0022-1317-81-7-1659

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  23 in total

1.  Genetic vaccination of mice with plasmids encoding the NS1 non-structural protein from tick-borne encephalitis virus and dengue 2 virus.

Authors:  A V Timofeev; V M Butenko; J R Stephenson
Journal:  Virus Genes       Date:  2004-01       Impact factor: 2.332

2.  The necessity and quandaries of dengue vaccine development.

Authors:  Stephen J Thomas
Journal:  J Infect Dis       Date:  2011-02-01       Impact factor: 5.226

3.  Development and application of a GuHCl-modified ELISA to measure the avidity of anti-HPV L1 VLP antibodies in vaccinated individuals.

Authors:  Joseph G Dauner; Yuanji Pan; Allan Hildesheim; Troy J Kemp; Carolina Porras; Ligia A Pinto
Journal:  Mol Cell Probes       Date:  2012-01-18       Impact factor: 2.365

4.  Dengue virus photo-inactivated in presence of 1,5-iodonaphthylazide (INA) or AMT, a psoralen compound (4'-aminomethyl-trioxsalen) is highly immunogenic in mice.

Authors:  Kanakatte Raviprakash; Peifang Sun; Yossef Raviv; Thomas Luke; Nicholas Martin; Tadeusz Kochel
Journal:  Hum Vaccin Immunother       Date:  2013-07-08       Impact factor: 3.452

5.  A dengue DNA vaccine formulated with Vaxfectin® is well tolerated, and elicits strong neutralizing antibody responses to all four dengue serotypes in New Zealand white rabbits.

Authors:  Kanakatte Raviprakash; Thomas Luke; John Doukas; Janine Danko; Kevin Porter; Timothy Burgess; Tadeusz Kochel
Journal:  Hum Vaccin Immunother       Date:  2012-10-02       Impact factor: 3.452

6.  Conserved MHC class I-presented dengue virus epitopes identified by immunoproteomics analysis are targets for cross-serotype reactive T-cell response.

Authors:  James S Testa; Vivekananda Shetty; Gomathinayagam Sinnathamby; Zacharie Nickens; Julie Hafner; Shivali Kamal; Xianchao Zhang; Marti Jett; Ramila Philip
Journal:  J Infect Dis       Date:  2012-01-13       Impact factor: 5.226

Review 7.  Viral kinetics of primary dengue virus infection in non-human primates: a systematic review and individual pooled analysis.

Authors:  Benjamin M Althouse; Anna P Durbin; Kathryn A Hanley; Scott B Halstead; Scott C Weaver; Derek A T Cummings
Journal:  Virology       Date:  2014-02-14       Impact factor: 3.616

8.  Two complex, adenovirus-based vaccines that together induce immune responses to all four dengue virus serotypes.

Authors:  David H Holman; Danher Wang; Kanakatte Raviprakash; Nicholas U Raja; Min Luo; Jianghui Zhang; Kevin R Porter; John Y Dong
Journal:  Clin Vaccine Immunol       Date:  2006-12-27

9.  A heterologous DNA prime-Venezuelan equine encephalitis virus replicon particle boost dengue vaccine regimen affords complete protection from virus challenge in cynomolgus macaques.

Authors:  Lan Chen; Dan Ewing; Hemavathy Subramanian; Karla Block; Jonathan Rayner; Kimberly D Alterson; Martha Sedegah; Curtis Hayes; Kevin Porter; Kanakatte Raviprakash
Journal:  J Virol       Date:  2007-08-22       Impact factor: 5.103

10.  A tetravalent dengue vaccine based on a complex adenovirus vector provides significant protection in rhesus monkeys against all four serotypes of dengue virus.

Authors:  Kanakatte Raviprakash; Danher Wang; Dan Ewing; David H Holman; Karla Block; Jan Woraratanadharm; Lan Chen; Curtis Hayes; John Y Dong; Kevin Porter
Journal:  J Virol       Date:  2008-05-14       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.